Latest Commercialisation News

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Livium Ltd reports a 179% surge in recycling gross profit and advances its lithium extraction technology, positioning itself strongly in the evolving battery materials market.

MTM Critical Metals reports solid progress on its US-based Flash Joule Heating demonstration plant, targeting a Q4 2025 start-up in Texas amid favorable regulatory and funding prospects.

Hiremii Limited reports a modest 0.4% revenue increase to $7.5 million in Q2 FY25, underpinned by strategic AI platform deployment and expanding Energy Transition sector opportunities.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Omega Oil and Gas Limited has successfully completed drilling and testing of its Canyon-1H horizontal well, revealing encouraging reservoir conditions that set the stage for upcoming fracture stimulation and flowback testing.

Reward Minerals has completed the acquisition of the Beyondie Potash Plant, positioning itself to advance its innovative potash processing technologies and reduce production costs. The move, funded through a non-dilutive loan extension, marks a significant step toward commercialising its patented SOP recovery methods.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

AnteoTech has marked a pivotal quarter with its first commercial Ultranode™ order shipped to Mercedes-Benz and a $4.3 million capital raise to accelerate growth in clean energy and life sciences.